KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Research & Development (2016 - 2025)

Abbott Laboratories' Research & Development history spans 17 years, with the latest figure at $735.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 1.87% year-over-year to $735.0 million; the TTM value through Dec 2025 reached $2.9 billion, up 3.45%, while the annual FY2025 figure was $2.9 billion, 3.45% up from the prior year.
  • Research & Development for Q4 2025 was $735.0 million at Abbott Laboratories, down from $766.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $782.0 million in Q3 2022 and bottomed at $654.0 million in Q1 2021.
  • The 5-year median for Research & Development is $706.5 million (2023), against an average of $707.8 million.
  • The largest annual shift saw Research & Development increased 16.37% in 2022 before it decreased 14.07% in 2023.
  • A 5-year view of Research & Development shows it stood at $762.0 million in 2021, then dropped by 4.86% to $725.0 million in 2022, then decreased by 3.45% to $700.0 million in 2023, then grew by 7.0% to $749.0 million in 2024, then decreased by 1.87% to $735.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABT's Research & Development are $735.0 million (Q4 2025), $766.0 million (Q3 2025), and $725.0 million (Q2 2025).